GLP-3RT
10mg · ≥99.4% Purity
Transparency
Certificate of Analysis
Every batch independently verified by third-party laboratories.
Batch #TL-2503
Analytical Formulations Inc.
All Trident Labs products are independently tested by accredited third-party laboratories. Results are batch-specific and provided for research transparency only. This product is not approved for human use.
The triple-incretin investigational analog under active study.
A 39-amino acid investigational peptide simultaneously engaging GLP-1R, GIPR, and GCGR. The only compound in its class to achieve sub-nanomolar binding at all three receptors. Examined across Phase 2 and Phase 3 peer-reviewed research.
Jastreboff et al. — 48-wk Phase 2 RCT. All data from peer-reviewed literature. For Research Use Only — Not for Human Consumption.
Preclinical Data
Published research
observations.
Data from peer-reviewed publications and Phase 2 trial registrations. Cited from independent published literature — not Trident Labs claims. For Research Use Only.
24%
Mean body weight change observed, 48 wks, 12 mg/wk vs placebo in Phase 2 RCT.
Jastreboff et al., NEJM 2023
3×
Receptor pathways activated simultaneously. No approved compound achieves this.
Phase 2 Mechanism Data
48wk
Phase 2 duration. No dose-response plateau in the highest-dose cohort at endpoint.
Eli Lilly Phase 2 Trial
2,500+
Participants enrolled across active Phase 3 TRIUMPH trials. Estimated completion 2026–27.
ClinicalTrials.gov
Dose-Response: Body Weight Change
Phase 2 RCT · % change from baseline at 48 weeks by weekly dose
Phase 2 RCT · N=338 · Jastreboff et al., NEJM 2023 [1]. In vitro research use only.
Mechanism of Action
Three pathways.
One molecule.
GLP-3RT binds all three receptors simultaneously — not sequentially, not partially. Each triggers a distinct and complementary pathway in preclinical models.
GLP-1 Receptor
Insulin secretion · Appetite signaling · Gastric emptying
0.04 nM
GIP Receptor
Adipocyte lipid metabolism · Insulin sensitization
0.06 nM
Glucagon Receptor
Hepatic glucose regulation · Thermogenesis · NASH
0.28 nM
Why the glucagon receptor changes everything
GCGR co-agonism engages hepatic and thermogenic pathways not activated by GLP-1R or GIPR alone. Preclinical NASH models have examined GCGR-associated hepatic fat changes and UCP-1 expression in brown adipose tissue (Sloop et al., Cell Metabolism 2022). These are in vitro and preclinical observations only.
Molecular Architecture
39 residues.
Three receptor targets.
GLP-3RT's backbone drawn residue-by-residue. GLP-1R-active residues in purple, GIPR-active in amber, GCGR-engaged in teal. The C18 acylation site and key structural modifications illuminate as the sequence completes.
Compound Comparison
Where GLP-3RT fits.
Three generations of research compounds at their highest studied doses.
Scroll to see full table
| Compound | GLP-1R | GIPR | GCGR | t½ | Phase | ΔBW |
|---|---|---|---|---|---|---|
| GLP-3RTTriple | ✓ | ✓ | ✓ | ~6d | Ph.3 | −24.2% |
| TirzepatideDual | ✓ | ✓ | — | ~5d | Appr. | −20.9% |
| SemaglutideSingle | ✓ | — | — | ~7d | Appr. | −14.9% |
| LiraglutideSingle | ✓ | — | — | 13hr | Appr. | −8.0% |
ΔBW = mean % change from baseline at highest-dose cohort in published peer-reviewed trials. Trial designs, populations, and durations differ significantly. Not a comparative effectiveness claim. All data from independent published literature. For Research Use Only — Not for Human Consumption.
Receptor Selectivity Profile
Triple agonism
visualized.
GLP-3RT's balanced triple-receptor engagement vs tirzepatide (dual) and semaglutide (mono). EC50 from in vitro cAMP assays — Coskun et al. J Med Chem 2022. Sub-nanomolar at all three receptors is the defining pharmacological characteristic of this compound class.
Coskun et al. J Med Chem 2022 · Willard et al. JCI Insight 2020 · Lau et al. J Med Chem 2015. In vitro data only. Research use only.
Pharmacokinetic Profile
~6-day half-life.
C18 acylation.
GLP-3RT uses the same C18 fatty diacid albumin-binding strategy as semaglutide, achieving a ~144-hour plasma half-life. Curve draws on scroll — compare against the class alongside the published first-in-human PK confirmation (Jastreboff NEJM 2023).
Compound Profile
Full specification
Molecular and pharmacological specs from published preclinical literature and Trident Labs batch records.
| Common Name | Retatrutide |
| Code | LY3437943 |
| Class | GLP-1 / GIP / Glucagon Triple Agonist |
| Structure | 39-amino acid acylated peptide |
| Mol. Weight | ~4.7 kDa |
| Half-Life | ~6 days (weekly dosing) |
| Acylation | C18 fatty diacid · albumin binding |
| Developer | Eli Lilly and Company |
| Phase | Phase 3 · TRIUMPH |
| Purity | ≥99.4% HPLC Verified |
| Form | Lyophilized powder · sealed vial |
| Regulatory | Research Use Only — Not for Human Use |
Receptor Binding Affinity
EC₅₀ from in vitro cAMP assays. Lower = stronger binding.
Sub-nanomolar binding at all three receptors. GLP-1R and GIPR both below 0.1 nM — the "balanced agonism" profile cited across Phase 2 summaries. In vitro only [2].
Why the C18 acyl chain matters
The C18 fatty diacid modification enables albumin binding, extending half-life to ~6 days. Same strategy as semaglutide — making once-weekly research dosing viable.
Research Context
Phase 3 active.
Most recent first.
Retatrutide has progressed from Phase 1 first-in-human to Phase 3 enrollment across multiple indications. Timeline sourced from published literature and ClinicalTrials.gov registrations.
Active preclinical & Phase 3 stage
Literature spans NASH/MASH, cardiovascular, and receptor pharmacology. One of the most actively studied metabolic peptides in current literature.
TRIUMPH Phase 3 initiated
Multiple parallel trials — metabolic, cardiovascular, hepatic (MASH), renal. Completion estimated 2026–27.
Phase 2 results published
Mean BW change of −24.2% at 48 weeks, no dose-response plateau observed at endpoint. Jastreboff et al., NEJM 2023 [1].
First-in-human PK/PD study
Confirms ~6-day half-life. 12 mg/wk tolerated. Weekly subcutaneous protocol established [6].
Initial synthesis & characterization
LY3437943 identified as balanced triple agonist. Sub-nM binding confirmed at all three receptors.
Key preclinical observations
No dose-response plateau observed at 48 weeks in any dose cohort — cited as notable in published Phase 2 analysis.
Jastreboff et al., NEJM 2023 [1]
GIPR co-agonism appears associated with attenuated GI adverse events in Phase 2 tolerability analysis.
Jastreboff et al., NEJM 2023 Phase 2 [1]
GCGR activation associated with hepatic fat reduction independent of caloric restriction in NASH models.
MASH Preclinical Models, 2023
Insulin sensitivity improvements observed independent of weight reduction, suggesting direct receptor-mediated effects.
Phase 2 Metabolic Substudy [1]
Storage & Handling
Stability specs.
Proper handling is the difference between a viable sample and a degraded one.
Pre-Reconstitution
−20°C
Sealed in freezer. Stable 24 months. Avoid frost-free — temp cycling degrades structure.
Post-Reconstitution
2–8°C
Transfer to 2–8°C immediately. Do not freeze reconstituted material — ice crystal formation disrupts peptide structure.
Reconstitution
BAC Water
2 mL BAC water per vial via calibrated laboratory syringe. Direct along interior vial wall slowly.
Critical Avoids
Avoid
No shaking or vortex. No UV light. Discard if cloudy or particulate after reconstitution.
Laboratory Reconstitution Reference
Standard laboratory procedure for qualified researchers. In vitro research use only.
Equilibrate to room temp
Remove from −20°C. Allow 15–20 min passive equilibration. Do not apply heat.
Add bacteriostatic water
Using a calibrated laboratory syringe, draw 2 mL BAC water. Direct solvent slowly along the interior glass wall — not onto the lyophilized cake.
Dissolve by rotation
Roll between palms 30–60 seconds until clear. Never shake or vortex.
Inspect and label
Should be clear, colorless to faint yellow. Discard if cloudy. Label with compound, concentration, date.
Label and refrigerate
Transfer immediately to 2–8°C. Label with compound name, lot number, and reconstitution date. Do not freeze reconstituted material.
Published Literature
All research on Retatrutide.
Independent peer-reviewed studies. Not Trident Labs claims.
Retatrutide (LY3437943) Phase 2 Dose-Finding Results — 48-Week RCT
Phase 2 RCT evaluating once-weekly subcutaneous retatrutide in adults with obesity. At 48 weeks, the 12 mg cohort achieved −24.2% mean body weight from baseline, with no plateau at endpoint. N=338 across 5 dose cohorts. GI adverse events dose-dependent and consistent with GLP-1R agonism.
Design and Characterization of LY3437943, a Novel Triple GIP, GLP-1, and Glucagon Receptor Agonist
Characterization of LY3437943 as a balanced acylated peptide agonist. In vitro cAMP assays confirmed sub-nanomolar EC50 at all three receptors: GLP-1R 0.04 nM, GIPR 0.06 nM, GCGR 0.28 nM. Preclinical in vivo models examined BW changes vs dual agonists at matched doses.
Glucagon Receptor Agonism in Triple Agonist Therapy: Hepatic Fat Reduction in MASH Models
Preclinical GCGR co-agonism study in MASH models. Significant reduction in hepatic triglyceride content and liver enzymes independent of caloric restriction. Thermogenesis observed concurrently with GLP-1R appetite signaling.
Cardiovascular Outcomes in GLP-1/GIP/Glucagon Triple Agonism: Evidence from LY3437943 Models
Preclinical CV safety and efficacy of triple receptor agonism. Reductions in systolic blood pressure, fasting glucose, and triglycerides. Cardiovascular parameters monitored through preclinical study duration. TRIUMPH-CVOT Phase 3 initiated.
GIPR Co-Agonism Attenuates GLP-1R-Mediated Nausea: Insight from Retatrutide Phase 2 Tolerability Data
GI tolerability analysis from the Phase 2 trial. GIPR co-agonism appears to attenuate GLP-1R-mediated nausea. Discontinuation rates lower than matched-dose semaglutide historical comparators.
Next-Generation Incretin Therapeutics: Systematic Review of Triple Receptor Agonism
Systematic review of 40+ studies on GLP-1/GIP/glucagon triple agonist pharmacology. Authors conclude that glucagon receptor co-agonism provides additive hepatic and thermogenic effects not achievable with dual agonism alone.
TRIUMPH-1: Phase 3 Trial of Retatrutide in Adults with Obesity (NCT05536804)
Pivotal Phase 3 trial of once-weekly retatrutide (12 mg) vs placebo, 2,500+ adults with BMI ≥30. Primary endpoint: % body weight change at 72 weeks. Estimated completion Q3 2026.
TRIUMPH-NASH: Phase 3 Evaluation of Retatrutide in Metabolic-Associated Steatohepatitis
Phase 3 trial in MASH with liver fibrosis. Primary endpoints: histological MASH resolution and ≥1 stage fibrosis improvement. Estimated enrollment: 700. Completion 2027.
Thermogenic Contribution of Glucagon Receptor Agonism: Brown Adipose Tissue Activation in DIO Models
GCGR agonism demonstrated significant brown adipose tissue activation (UCP-1 expression, oxygen consumption) in DIO models. The thermogenic effect was additive to GLP-1R appetite suppression and GIPR adipocyte lipid handling.
Indexed from PubMed, ClinicalTrials.gov, and peer-reviewed journals. Independent published research — not Trident Labs claims. GLP-3RT (Retatrutide) is an investigational compound currently in Phase 3. For Research Use Only — Not for Human Consumption. Not a drug, food, dietary supplement, cosmetic, or medical device. For lawful laboratory research use only by qualified researchers.
Cited Sources
References
All scientific claims sourced from peer-reviewed literature or official trial registrations.
Tirzepatide Once Weekly for the Treatment of Obesity — Retatrutide Phase 2 Dose-Finding Study
LY3437943, a Novel Triple GIP, GLP-1, and Glucagon Receptor Agonist for Glycemic Control and Weight Loss
Glucagon Receptor Agonism and Hepatic Fat Reduction in MASH Preclinical Models
Thermogenic Contribution of Glucagon Receptor Agonism: Brown Adipose Tissue Activation in DIO Models Treated with LY3437943
Similar Pharmacokinetics of Semaglutide and LY3437943 Enabled by C18 Fatty Diacid Acylation
First-in-Human Phase 1 Study of LY3437943: Safety, Tolerability, and Pharmacokinetics
TRIUMPH-1: A Phase 3 Study of Retatrutide in Participants with Obesity
Next-Generation Incretin Therapeutics: Systematic Review of Triple GLP-1/GIP/Glucagon Receptor Agonism
Support
Frequently Asked Questions
Everything you need to know about this product and your order.
